Second-Line Irinotecan vs. ILF for AGC

NCT00509964 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasm
Metastatic
Second-Line

Interventions

DRUG: irinotecan
DRUG: ILF

Sponsor

Gachon University Gil Medical Center